Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Konkret geht es um den Diabetes-Patienten mit kardiovaskulären Erkrankungen oder Risiken, die Herzinsuffizienz sowie die kardiovaskuläre Primär- und Sekundärprävention. Sind Sie hier schon auf dem neuesten Stand? Unsere Experten beleuchten, wo und warum das bisherige Procedere geändert werden soll und was in der Praxis sinnvoll ist. Holen Sie sich Ihr Update und 2 CME-Punkte beim MMW-Webinar am 24. April von 17.30 bis 19 Uhr. 
Erweiterte Suche
Anmelden
nach oben
Inflammation
Erschienen in: Inflammation 5/2014

01.10.2014

Therapeutic Potential of HO-1 in Autoimmune Diseases

verfasst von: Bao-Zhu Li, Biao Guo, Hai-Yan Zhang, Juan Liu, Sha-Sha Tao, Hai-Feng Pan, Dong-Qing Ye

Erschienen in: Inflammation | Ausgabe 5/2014

Einloggen, um Zugang zu erhalten

Abstract

Heme oxygenase-1 (HO-1), the inducible isoform of heme oxygenase (HO), has raised a lot of concerns in recent years due to its multiple functions. HO-1 was found to be a pivotal cytoprotective, antioxidant, anti-apoptotic, immunosuppressive, as well as anti-inflammatory molecule. Recent studies have clarified its significant functions in many diseases with substantial findings. In autoimmune diseases, HO-1 may have promising therapeutic potential. Here, we briefly reviewed recent advances in this field, aiming at hopefully exploring the potential therapeutic roles of HO-1, and design HO-1-based strategies for the treatment of autoimmune diseases.
Literatur
1.
Kapturczak, M.H., C. Wasserfall, T. Brusko, et al. 2004. Heme oxygenase-1 modulates early inflammatory responses: Evidence from the heme oxygenase-1-deficient mouse. The American Journal of Pathology 165: 1045–1053.PubMedCrossRefPubMedCentral
2.
Tenhunen, R., H.S. Marver, and R. Schmid. 1968. The enzymatic conversion of heme to bilirubin by microsomal heme oxygenase. Proceedings of the National Academy of Sciences of the United States of America 61: 748–755.PubMedCrossRefPubMedCentral
3.
Durante, W. 2011. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Frontiers in Bioscience (Landmark Ed) 16: 2372–2388.CrossRef
4.
Kobayashi, H., M. Takeno, T. Saito, et al. 2006. Regulatory role of heme oxygenase 1 in inflammation of rheumatoid arthritis. Arthritis and Rheumatism 54: 1132–1142.PubMedCrossRef
5.
Minamino, T., H. Christou, C.M. Hsieh, et al. 2001. Targeted expression of heme oxygenase-1 prevents the pulmonary inflammatory and vascular responses to hypoxia. Proceedings of the National Academy of Sciences of the United States of America 98: 8798–8803.PubMedCrossRefPubMedCentral
6.
Haines, D.D., I. Lekli, P. Teissier, I. Bak, and A. Tosaki. 2012. Role of haeme oxygenase-1 in resolution of oxidative stress-related pathologies: Focus on cardiovascular, lung, neurological and kidney disorders. Acta Physiologica (Oxford, England) 204: 487–501.CrossRef
7.
Blancou, P., V. Tardif, T. Simon, et al. 2011. Immunoregulatory properties of heme oxygenase-1. Methods in Molecular Biology 677: 247–268.PubMedCrossRef
8.
Fagone, P., F. Patti, K. Mangano, et al. 2013. Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis. Journal of Neuroimmunology 261: 82–86.PubMedCrossRef
9.
Simon, T., I. Anegon, and P. Blancou. 2011. Heme oxygenase and carbon monoxide as an immunotherapeutic approach in transplantation and cancer. Immunotherapy 3: 15–18.PubMedCrossRef
10.
Poss, K.D., and S. Tonegawa. 1997. Heme oxygenase 1 is required for mammalian iron reutilization. Proceedings of the National Academy of Sciences of the United States of America 94: 10919–10924.PubMedCrossRefPubMedCentral
11.
Yachie, A., Y. Niida, T. Wada, et al. 1999. Oxidative stress causes enhanced endothelial cell injury in human heme oxygenase-1 deficiency. The Journal of Clinical Investigation 103: 129–135.PubMedCrossRefPubMedCentral
12.
Pae, H.O., G.S. Oh, B.M. Choi, et al. 2004. Carbon monoxide produced by heme oxygenase-1 suppresses T cell proliferation via inhibition of IL-2 production. Journal of Immunology 172: 4744–4751.CrossRef
13.
Burt, T.D., L. Seu, J.E. Mold, A. Kappas, and J.M. McCune. 2010. Naive human T cells are activated and proliferate in response to the heme oxygenase-1 inhibitor tin mesoporphyrin. Journal of Immunology 185: 5279–5288.CrossRef
14.
Hu, C.M., H.H. Lin, M.T. Chiang, P.F. Chang, and L.Y. Chau. 2007. Systemic expression of heme oxygenase-1 ameliorates type 1 diabetes in NOD mice. Diabetes 56: 1240–1247.PubMedCrossRef
15.
Xia, Z.W., W.W. Zhong, L.Q. Xu, et al. 2006. Heme oxygenase-1-mediated CD4+CD25high regulatory T cells suppress allergic airway inflammation. Journal of Immunology 177: 5936–5945.CrossRef
16.
Gu, Q., Q. Wu, M. Jin, et al. 2012. Heme oxygenase-1 alleviates mouse hepatic failure through suppression of adaptive immune responses. The Journal of Pharmacology and Experimental Therapeutics 340: 2–10.PubMedCrossRef
17.
Chauveau, C., S. Remy, P.J. Royer, et al. 2005. Heme oxygenase-1 expression inhibits dendritic cell maturation and proinflammatory function but conserves IL-10 expression. Blood 106: 1694–1702.PubMedCrossRef
18.
Remy, S., P. Blancou, L. Tesson, et al. 2009. Carbon monoxide inhibits TLR-induced dendritic cell immunogenicity. Journal of Immunology 182: 1877–1884.CrossRef
19.
George, J.F., A. Braun, T.M. Brusko, et al. 2008. Suppression by CD4+ CD25+ regulatory T cells is dependent on expression of heme oxygenase-1 in antigen-presenting cells. The American Journal of Pathology 173: 154–160.PubMedCrossRefPubMedCentral
20.
Park, D.J., A. Agarwal, and J.F. George. 2010. Heme oxygenase-1 expression in murine dendritic cell subpopulations: Effect on CD8+ dendritic cell differentiation in vivo. The American Journal of Pathology 176: 2831–2839.PubMedCrossRefPubMedCentral
21.
Tardif, V., S.A. Riquelme, S. Remy, et al. 2013. Carbon monoxide decreases endosome-lysosome fusion and inhibits soluble antigen presentation by dendritic cells to T cells. European Journal of Immunology 43(11): 2832–2844.PubMedCrossRef
22.
Chora, A.A., P. Fontoura, A. Cunha, et al. 2007. Heme oxygenase-1 and carbon monoxide suppress autoimmune neuroinflammation. The Journal of Clinical Investigation 117: 438–447.PubMedCrossRefPubMedCentral
23.
Xia, Z.W., W.W. Zhong, J.S. Meyrowitz, and Z.L. Zhang. 2008. The role of heme oxygenase-1 in T cell-mediated immunity: The all encompassing enzyme. Current Pharmaceutical Design 14: 454–464.PubMedCrossRef
24.
Weaver, C.T., L.E. Harrington, P.R. Mangan, M. Gavrieli, and K.M. Murphy. 2006. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 24: 677–688.PubMedCrossRef
25.
Deenick, E.K., and S.G. Tangye. 2007. Autoimmunity: IL-21: A new player in Th17-cell differentiation. Immunology and Cell Biology 85: 503–505.PubMedCrossRef
26.
Bettelli, E., Y. Carrier, W. Gao, et al. 2006. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441: 235–238.PubMedCrossRef
27.
Zhang, Y., L. Zhang, J. Wu, C. Di, and Z. Xia. 2013. Heme oxygenase-1 exerts a protective role in ovalbumin-induced neutrophilic airway inflammation by inhibiting response in the immune cells Th17. The Journal of Biological Chemistry 288(48): 34612–34626.PubMedCrossRef
28.
Otterbein, L.E., M.P. Soares, K. Yamashita, and F.H. Bach. 2003. Heme oxygenase-1: Unleashing the protective properties of heme. Trends in Immunology 24: 449–455.PubMedCrossRef
29.
Lee, T.S., and L.Y. Chau. 2002. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nature Medicine 8: 240–246.PubMedCrossRef
30.
Mackern-Oberti, J.P., C. Llanos, L.J. Carreno, et al. 2013. Carbon monoxide exposure improves immune function in lupus-prone mice. Immunology 140: 123–132.PubMedCrossRefPubMedCentral
31.
Otterbein, L.E., F.H. Bach, J. Alam, et al. 2000. Carbon monoxide has anti-inflammatory effects involving the mitogen-activated protein kinase pathway. Nature Medicine 6: 422–428.PubMedCrossRef
32.
Bilban, M., F.H. Bach, S.L. Otterbein, et al. 2006. Carbon monoxide orchestrates a protective response through PPARgamma. Immunity 24: 601–610.PubMedCrossRef
33.
Woo, C.H., M.P. Massett, T. Shishido, et al. 2006. ERK5 activation inhibits inflammatory responses via peroxisome proliferator-activated receptor delta (PPARdelta) stimulation. The Journal of Biological Chemistry 281: 32164–32174.PubMedCrossRef
34.
Nakahira, K., H.P. Kim, X.H. Geng, et al. 2006. Carbon monoxide differentially inhibits TLR signaling pathways by regulating ROS-induced trafficking of TLRs to lipid rafts. The Journal of Experimental Medicine 203: 2377–2389.PubMedCrossRefPubMedCentral
35.
Wang, X.M., H.P. Kim, K. Nakahira, S.W. Ryter, and A.M. Choi. 2009. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1. Journal of Immunology 182: 3809–3818.CrossRef
36.
Chin, B.Y., G. Jiang, B. Wegiel, et al. 2007. Hypoxia-inducible factor 1alpha stabilization by carbon monoxide results in cytoprotective preconditioning. Proceedings of the National Academy of Sciences of the United States of America 104: 5109–5114.PubMedCrossRefPubMedCentral
37.
Rahman, A., and D.A. Isenberg. 2008. Systemic lupus erythematosus. The New England Journal of Medicine 358: 929–939.PubMedCrossRef
38.
Herrada, A.A., C. Llanos, J.P. Mackern-Oberti, et al. 2012. Haem oxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus. Immunology 136: 414–424.PubMedCrossRefPubMedCentral
39.
Chung, S.W., X. Liu, A.A. Macias, R.M. Baron, and M.A. Perrella. 2008. Heme oxygenase-1-derived carbon monoxide enhances the host defense response to microbial sepsis in mice. The Journal of Clinical Investigation 118: 239–247.PubMedCrossRefPubMedCentral
40.
Avihingsanon, Y., T. Benjachat, A. Tassanarong, P. Sodsai, V. Kittikovit, and N. Hirankarn. 2009. Decreased renal expression of vascular endothelial growth factor in lupus nephritis is associated with worse prognosis. Kidney International 75: 1340–1348.PubMedCrossRef
41.
Takeda, Y., M. Takeno, M. Iwasaki, et al. 2004. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clinical and Experimental Immunology 138: 237–244.PubMedCrossRefPubMedCentral
42.
Burmester, G.R., B. Stuhlmuller, G. Keyszer, and R.W. Kinne. 1997. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis and Rheumatism 40: 5–18.PubMedCrossRef
43.
Feldmann, M., F.M. Brennan, and R.N. Maini. 1996. Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14: 397–440.PubMedCrossRef
44.
Choy, E.H., and G.S. Panayi. 2001. Cytokine pathways and joint inflammation in rheumatoid arthritis. The New England Journal of Medicine 344: 907–916.PubMedCrossRef
45.
Devesa, I., M.L. Ferrandiz, M.C. Terencio, L.A. Joosten, W.B. van den Berg, and M.J. Alcaraz. 2005. Influence of heme oxygenase 1 modulation on the progression of murine collagen-induced arthritis. Arthritis and Rheumatism 52: 3230–3238.PubMedCrossRef
46.
Kirino, Y., M. Takeno, S. Murakami, et al. 2007. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. Arthritis and Rheumatism 56: 464–475.PubMedCrossRef
47.
Kitamura, A., K. Nishida, T. Komiyama, et al. 2011. Increased level of heme oxygenase-1 in rheumatoid arthritis synovial fluid. Modern Rheumatology 21: 150–157.PubMedCrossRef
48.
Devesa, I., M.L. Ferrandiz, I. Guillen, J.M. Cerda, and M.J. Alcaraz. 2005. Potential role of heme oxygenase-1 in the progression of rat adjuvant arthritis. Laboratory Investigation 85: 34–44.PubMedCrossRef
49.
Benallaoua, M., M. Francois, F. Batteux, et al. 2007. Pharmacologic induction of heme oxygenase 1 reduces acute inflammatory arthritis in mice. Arthritis and Rheumatism 56: 2585–2594.PubMedCrossRef
50.
Chi, P.L., Y.W. Chen, L.D. Hsiao, Y.L. Chen, and C.M. Yang. 2012. Heme oxygenase 1 attenuates interleukin-1beta-induced cytosolic phospholipase A2 expression via a decrease in NADPH oxidase/reactive oxygen species/activator protein 1 activation in rheumatoid arthritis synovial fibroblasts. Arthritis and Rheumatism 64: 2114–2125.PubMedCrossRef
51.
Bonelli, M., A. Savitskaya, C.W. Steiner, et al. 2012. Heme oxygenase-1 end-products carbon monoxide and biliverdin ameliorate murine collagen induced arthritis. Clinical and Experimental Rheumatology 30: 73–78.PubMed
52.
Noseworthy, J.H., C. Lucchinetti, M. Rodriguez, and B.G. Weinshenker. 2000. Multiple sclerosis. The New England Journal of Medicine 343: 938–952.PubMedCrossRef
53.
Le, W.D., W.J. Xie, and S.H. Appel. 1999. Protective role of heme oxygenase-1 in oxidative stress-induced neuronal injury. Journal of Neuroscience Research 56: 652–658.PubMedCrossRef
54.
Schluesener, H.J., and K. Seid. 2000. Heme oxygenase-1 in lesions of rat experimental autoimmune encephalomyelitis and neuritis. Journal of Neuroimmunology 110: 114–120.PubMedCrossRef
55.
Liu, Y., B. Zhu, L. Luo, P. Li, D.W. Paty, and M.S. Cynader. 2001. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 12: 1841–1845.PubMedCrossRef
56.
Swanborg, R.H. 1995. Experimental autoimmune encephalomyelitis in rodents as a model for human demyelinating disease. Clinical Immunology and Immunopathology 77: 4–13.PubMedCrossRef
57.
Rivers, T.M., and F.F. Schwentker. 1935. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. The Journal of Experimental Medicine 61: 689–702.PubMedCrossRefPubMedCentral
58.
Chen, S.J., Y.L. Wang, W.T. Lo, et al. 2010. Erythropoietin enhances endogenous haem oxygenase-1 and represses immune responses to ameliorate experimental autoimmune encephalomyelitis. Clinical and Experimental Immunology 162: 210–223.PubMedCrossRefPubMedCentral
59.
DeVry, C.G., M. Valdez, L. Gao, et al. 2004. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. Journal of Neuroimmunology 152: 33–43.PubMedCrossRef
60.
Tzima, S., P. Victoratos, K. Kranidioti, M. Alexiou, and G. Kollias. 2009. Myeloid heme oxygenase-1 regulates innate immunity and autoimmunity by modulating IFN-beta production. The Journal of Experimental Medicine 206: 1167–1179.PubMedCrossRefPubMedCentral
61.
Chakrabarty, A., M.R. Emerson, and S.M. LeVine. 2003. Heme oxygenase-1 in SJL mice with experimental allergic encephalomyelitis. Multiple Sclerosis 9: 372–381.PubMedCrossRef
62.
63.
Di Filippo, C., R. Marfella, S. Cuzzocrea, et al. 2005. Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. Diabetes 54: 803–810.PubMedCrossRef
64.
Rodella, L., B.D. Lamon, R. Rezzani, et al. 2006. Carbon monoxide and biliverdin prevent endothelial cell sloughing in rats with type I diabetes. Free Radical Biology & Medicine 40: 2198–2205.CrossRef
65.
Li, M., S. Peterson, D. Husney, et al. 2007. Long-lasting expression of HO-1 delays progression of type I diabetes in NOD mice. Cell Cycle 6: 567–571.PubMedCrossRef
66.
Huang, S.H., C.H. Chu, J.C. Yu, et al. 2010. Transgenic expression of haem oxygenase-1 in pancreatic beta cells protects non-obese mice used as a model of diabetes from autoimmune destruction and prolongs graft survival following islet transplantation. Diabetologia 53: 2389–2400.PubMedCrossRef
67.
Abdel Aziz, M.T., M.F. El-Asmar, E.G. El Nadi, et al. 2010. The effect of curcumin on insulin release in rat-isolated pancreatic islets. Angiology 61: 557–566.PubMedCrossRef
68.
Abdel Aziz, M.T., M.F. El-Asmar, I.N. El-Ibrashy, et al. 2012. Effect of novel water soluble curcumin derivative on experimental type- 1 diabetes mellitus (short term study). Diabetology and Metabolic Syndrome 4: 30.PubMedCrossRefPubMedCentral
69.
Shibahara, S. 2003. The heme oxygenase dilemma in cellular homeostasis: New insights for the feedback regulation of heme catabolism. The Tohoku Journal of Experimental Medicine 200: 167–186.PubMedCrossRef
70.
Wagener, F.A., E.J. Toonen, L. Wigman, et al. 2008. HMOX1 promoter polymorphism modulates the relationship between disease activity and joint damage in rheumatoid arthritis. Arthritis and Rheumatism 58: 3388–3393.PubMedCrossRef
71.
Cordova, E.J., A. Martinez-Hernandez, J. Ramirez-Bello, et al. 2012. HMOX1 promoter (GT)n polymorphim is associated with childhood-onset systemic lupus erythematosus but not with juvenile rheumatoid arthritis in a Mexican population. Clinical and Experimental Rheumatology 30: 297–301.PubMed
72.
Rueda, B., J. Oliver, G. Robledo, et al. 2007. HO-1 promoter polymorphism associated with rheumatoid arthritis. Arthritis and Rheumatism 56: 3953–3958.PubMedCrossRef
Metadaten
Titel
Therapeutic Potential of HO-1 in Autoimmune Diseases
verfasst von
Bao-Zhu Li
Biao Guo
Hai-Yan Zhang
Juan Liu
Sha-Sha Tao
Hai-Feng Pan
Dong-Qing Ye
Publikationsdatum
01.10.2014
Verlag
Springer US
Erschienen in
Inflammation / Ausgabe 5/2014
Print ISSN: 0360-3997
Elektronische ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-014-9908-z

Weitere Artikel der Ausgabe 5/2014

Inflammation 5/2014 Zur Ausgabe

OriginalPaper

Sulforaphane Inhibits IL-1β-Induced Proliferation of Rheumatoid Arthritis Synovial Fibroblasts and the Production of MMPs, COX-2, and PGE2

OriginalPaper

Bufalin Exerts Inhibitory Effects on IL-1β-Mediated Proliferation and Induces Apoptosis in Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes

OriginalPaper

In Vivo and In Vitro Immunomodulatory Potential of Swertiamarin Isolated from Enicostema axillare (Lam.) A. Raynal That Acts as an Anti-inflammatory Agent

OriginalPaper

Identification of Potential Serum Biomarkers for Rheumatoid Arthritis by High-Resolution Quantitative Proteomic Analysis

OriginalPaper

Platelet Factor 4 Inhibits IL-17/Stat3 Pathway via Upregulation of SOCS3 Expression in Melanoma

OriginalPaper

RAGE/NF-κB Pathway Mediates Lipopolysaccharide-Induced Inflammation in Alveolar Type I Epithelial Cells Isolated from Neonate Rats

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

23.04.2024 | Prävention und Rehabilitation in der Kardiologie | Nachrichten

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

23.04.2024 | Appendizitis | Nachrichten

Hinter dieser Appendizitis steckte ein Erreger

23.04.2024 | Demenz | Nachrichten

Demenzkranke durch Antipsychotika vielfach gefährdet
weitere anzeigen

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise